Neurocrine Biosciences, Inc. (NBIX)
收市後：
- InvestorPlace
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one’s health. If you can’t enjoy the fruits of your labor, then your labor will be meaningless. That’s why healthcare as a sector performs so well. Of course, being tied to a permanently relevant narrative doesn’t guarantee any individual enterprise success. However, one thing is c
- Investor's Business Daily
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences continues to put up really healthy numbers, with an ostensible 335% profit hike on a powerful reversal last quarter. On Friday, Neurocrine Biosciences stock got a Relative Strength (RS) Rating upgrade from 77 to 82. The upgraded 82 RS Rating means Neurocrine Biosciences stock is among the top 18% overall for price performance over the past year.
- Investor's Business Daily
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Neurocrine Biosciences is making good on its promise to diversify from Ingrezza. Meanwhile, the biotech stock is angling for a record.
